Back to Search Start Over

Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients

Authors :
Goran B. Klintmalm
B. M. Susskind
Linda Jennings
Paul I. Terasaki
Jacqueline G. O'Leary
Hugo Kaneku
Source :
Liver Transplantation. 20:655-663
Publication Year :
2014
Publisher :
Ovid Technologies (Wolters Kluwer Health), 2014.

Abstract

Hepatitis C virus (HCV) fibrosis progression after liver transplantation (LT) is accelerated in comparison with fibrosis progression before transplantation. The vast majority of the risk factors for fibrosis progression after LT are not modifiable. With the goal of identifying modifiable risk factors for fibrosis progression, we evaluated the impact of preformed and de novo donor-specific human leukocyte antigen alloantibodies (DSAs) on fibrosis progression after LT in HCV-viremic patients. After blinding, we analyzed all 507 HCV-viremic patients who underwent primary LT from January 2000 to May 2009 and had pretransplant and posttransplant samples available for analysis (86% of the total) for preformed and de novo class I and class II DSAs with a mean fluorescence intensity ≥ 5000 with single-antigen bead technology. Fibrosis was assessed on the basis of indication and protocol liver biopsies; compliance with protocol liver biopsies at 1, 2, and 5 years was ≥80%. Preformed class I DSAs [hazard ratio (HR) = 1.44, P = 0.04] and class II DSAs (HR = 1.86, P

Details

ISSN :
15276465
Volume :
20
Database :
OpenAIRE
Journal :
Liver Transplantation
Accession number :
edsair.doi...........e4a995b8c2b7069578f23b08727e4b1d
Full Text :
https://doi.org/10.1002/lt.23854